article · Cureus
This case report describes a 69-year-old Nigerian man diagnosed with two distinct urologic cancers: prostate adenocarcinoma and chromophobe renal cell carcinoma (ChRCC). He initially presented with prostate cancer, which was treated with brachytherapy and external beam radiotherapy. Two years later, a renal mass was discovered. Although initial histology suggested a benign tumour, further immunohistochemical analysis confirmed it to be ChRCC. This unusual co-occurrence highlights the complexities in diagnosing and managing patients with multiple urologic conditions. The case underscores the critical role of detailed histopathologic examination and advanced diagnostic techniques like immunohistochemistry in confirming diagnoses, especially when initial findings are ambiguous. It also emphasises the need for vigilant long-term follow-up for patients with intricate medical histories.
This case demonstrates the challenges in diagnosing and managing rare co-occurring cancers. It underscores the importance of advanced diagnostic tools and careful patient monitoring to ensure accurate treatment and better outcomes, especially when initial findings are unclear, thereby improving patient care.
The abstract describes a specific clinical case and does not indicate an application pathway for commercialisation.
AI-generated from the published abstract. Always read the original work before citing.
Prostate adenocarcinoma and chromophobe renal cell carcinoma (ChRCC) are two distinct urologic malignancies with different prognoses and treatment approaches. The occurrence of both tumors in the same individual is highly unusual. We describe the case of a 69-year-old man with a long-standing history of hypertension who had previously undergone prostatectomy for benign prostatic hyperplasia. In 2022, he re-presented with recurrent lower urinary tract symptoms. Biopsy confirmed acinar adenocarcinoma of the prostate (Gleason 4+3), and magnetic resonance imaging (MRI) staged the disease as T3aN0M0. He was treated with high-dose-rate (HDR) brachytherapy followed by external beam radiotherapy (EBRT). Two years later, a right renal mass was detected. While the initial histology favored oncocytoma, immunohistochemistry revealed strong cytokeratin (CK)7 expression with focal CD117 staining, confirming the eosinophilic subtype of ChRCC. This case illustrates the importance of thorough histopathologic work-up of renal lesions, the diagnostic value of immunohistochemistry, and the need for careful follow-up in patients with complex urologic histories.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.7759/cureus.100211
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
